申请人:Texas Biotechnology Corporation
公开号:US05571821A1
公开(公告)日:1996-11-05
Sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided. The sulfonamides have formula I: ##STR1## in which Ar.sup.1 is a 3- or 5-isoxazolyl and Ar.sup.2 is selected from among alkyl, including straight and branched chains, aromatic rings, fused aromatic rings and heterocyclic rings, including 5-membered heterocycles with one, two or more heteroatoms and fused ring analogs thereof and 6-membered rings with one, two or more heteroatoms and fused ring analogs thereof. Ar.sup.2 is preferably thiophenyl, furyl, pyrrolyl, naphthyl, and phenyl. Compounds in which Ar.sup.1 is a 4-halo-substituted isoxazole are more active than the corresponding alkyl-substituted compound and compounds in which Ar.sup.1 is substituted at this position with a higher alkyl tend to exhibit greater affinity for ET.sub.B receptors than the corresponding lower alkyl-substituted compound.
提供了一种使用磺胺类化合物抑制内皮素肽与内皮素受体结合的方法,该方法是通过将磺胺类化合物与受体接触实现的。还提供了一种治疗内皮素介导疾病的方法,该方法是通过给予一种或多种有效量的磺胺类化合物或其前药,该化合物或前药能够抑制或增加内皮素的活性。磺胺类化合物的化学式为I:##STR1## 其中Ar.sup.1是3-或5-异恶唑基,Ar.sup.2选自烷基,包括直链和支链,芳香环,融合的芳香环和杂环,包括带有一个、两个或多个杂原子的5-成员杂环和其融合环的类似物以及带有一个、两个或多个杂原子的6-成员环和其融合环的类似物。Ar.sup.2优选为噻吩基,呋喃基,吡咯基,萘基和苯基。其中,Ar.sup.1为4-卤代异恶唑基的化合物比相应的烷基取代化合物更活性,而Ar.sup.1在该位置上取代较高烷基的化合物往往表现出比相应的较低烷基取代化合物更大的亲和力ET.sub.B受体。